Decitabine Synergizes with Replication Checkpoint Inhibitors in TP53-Mutated Acute Myeloid Leukemia

被引：0
|
作者：
Csizmar, Clifford M. [1 ]
Saliba, Antoine N. [1 ]
Peterson, Kevin L. [2 ]
Meng, Xue Wei [2 ]
Smith, B. Douglas [3 ]
Ghiaur, Gabriel [4 ]
Patnaik, Mrinal M. [1 ]
Kaufmann, Scott H. [5 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Oncol, Div Oncol Res, Rochester, MN USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Dept Med Oncol, Div Hematol Malignancies, Baltimore, MD USA
[5] Mayo Clin, Dept Med, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208583
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5782 / 5783
页数：2
相关论文
共 50 条
  • [1] TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
    Testa, Ugo
    Castelli, Germana
    Pelosi, Elvira
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2023, 15 (01)
  • [2] Precision medicine for TP53-mutated acute myeloid leukemia
    Brattas, Marte Karen
    Reikvam, Hakon
    Tvedt, Tor Henrik Anderson
    Bruserud, Oystein
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (05): : 263 - 274
  • [3] Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting cell cycle checkpoint
    Gwak, Daehyeon
    Kim, Dongchan
    Jang, Heejun
    Liu, Jun
    Min, Suji
    Byun, Ja Min
    Koh, Youngil
    Hong, Junshik
    Yoon, Sung-Soo
    Shin, Dong-Yeop
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Decitabine in TP53-Mutated AML
    Montalban-Bravo, Guillermo
    Takahashi, Koichi
    Garcia-Manero, Guillermo
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (08): : 796 - 797
  • [5] Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia
    Vanttinen, Ida
    Ruokoranta, Tanja
    Saad, Joseph J.
    Kytola, Sari
    Hellesoy, Monica
    Gullaksen, Stein-Erik
    Ettala, Pia-Sofia
    Pyorala, Marja
    Rimpilainen, Johanna
    Siitonen, Timo
    Wennerberg, Krister
    Gjertsen, Bjorn T.
    Heckman, Caroline A.
    Kontro, Mika
    Kuusanmaki, Heikki
    BLOOD, 2023, 142
  • [6] Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
    Ferraro, Francesca
    Gruszczynska, Agata
    Ruzinova, Marianna B.
    Miller, Christopher A.
    Percival, Mary Elizabeth
    Uy, Geoffrey L.
    Pusic, Iskra
    Jacoby, Meagan A.
    Christopher, Mathew J.
    Kim, Miriam Y.
    Westervelt, Peter
    Cashen, Amanda F.
    Schroeder, Mark A.
    DiPersio, John F.
    Abboud, Camille N.
    Wartman, Lukas D.
    Gao, Feng
    Link, Daniel C.
    Ley, Timothy J.
    Welch, John S.
    HAEMATOLOGICA, 2022, 107 (07) : 1709 - 1713
  • [7] TP53-Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges
    Ghimire, Bipin
    Zimmer, Markie
    Donthireddy, Vijayalakshmi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025,
  • [8] Decitabine in TP53-Mutated AML Reply
    Welch, John S.
    Petti, Allegra A.
    Ley, Timothy J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (08): : 797 - 798
  • [9] Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
    Shallis, Rory M.
    Bewersdorf, Jan P.
    Stahl, Maximilian F.
    Halene, Stephanie
    Zeidan, Amer M.
    CANCERS, 2022, 14 (10)
  • [10] Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
    Granowicz, Eric M.
    Jonas, Brian A.
    ONCOTARGETS AND THERAPY, 2022, 15 : 423 - 436
12345